Journal of Neurology

, Volume 239, Issue 2, pp 103–104

Brain muscarinic cholinergic receptors in Huntington's disease

Authors

  • K. W. Lange
    • University Department of Clinical Neurology, Institute of Neurology and The National Hospital for Neurology and Neurosurgery
    • Pharmacology Group, Biomedical Sciences DivisionKing's College
  • F. Javoy-Agid
    • Laboratoire de Médicine Expérimentale, INSERM U. 289Hôpital de la Salpêtrière
  • Y. Agid
    • Laboratoire de Médicine Expérimentale, INSERM U. 289Hôpital de la Salpêtrière
  • P. Jenner
    • Pharmacology Group, Biomedical Sciences DivisionKing's College
  • C. D. Marsden
    • University Department of Clinical Neurology, Institute of Neurology and The National Hospital for Neurology and Neurosurgery
Original Communications

DOI: 10.1007/BF00862983

Cite this article as:
Lange, K.W., Javoy-Agid, F., Agid, Y. et al. J Neurol (1992) 239: 103. doi:10.1007/BF00862983

Summary

Muscarinic cholinergic receptors and choline acetyltransferase (ChAT) activity were studied in postmortem brain tissue from patients with Huntington's disease and matched control subjects. In comparison with controls, reductions in ChAT activity were found in the hippocampus, but not in the temporal cortex in Huntington's disease. Patients with Huntington's disease showed reduced densities of the total number of muscarinic receptors and of M-2 receptors in the hippocampus while the density of M-1 receptors was unaltered. Muscarinic receptor binding was unchanged in the temporal cortex. These results indicate a degeneration in Huntington's disease of the septo-hippocampul cholinergic pathway, but no impairment of the innominato-cortical cholinergic system.

Key words

Acetylcholine Choline acetyltransferase Muscarinic receptors Huntington's disease

Copyright information

© Springer-Verlag 1992